MindMate partners with Actinogen to discover Alzheimer’s treatment
The partnership will see Actinogen use Glasgow-based MindMate’s cognitive health software to recruit patients for the Australian company’s pioneering XanADu trial, currently in Phase 2, to prove the effectiveness of its Xanamem drug in patients with Alzheimer’s.
Xanamem aims to inhibit the excess production of the stress hormone cortisol in the brain, and was developed in response to evidence that high cortisol levels have a strong association with Alzheimer’s.
Because a high number of clinical trials fail to meet recruitment goals, leading to delays, increased costs and inadequate results, the partnership will allow Actinogen to identify the right patient population faster.
MindMate has integrated with Actinogen’s clinical trial and will support patient recruitment in the US, Australia and UK. The University of Edinburgh is one of Actinogen’s partner sites for the XanADu trial.
Susanne Mitschke, MindMate’s CEO and co-founder, said: “This partnership is a fantastic opportunity to collaborate with one of the leading research organizations in Scotland and shows that Scotland is continuing to drive innovation also through world-leading biotech developments.”
In the UK alone, more than 850,000 people live with Alzheimer’s and this number is projected to increase to over 1 million over the next six years.
In Q1 of 2018, MindMate raised approximately $2m from a series of international investors to accelerate new therapies in the clinical research space.
Published: 11 July 2018